Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin
Published 3 months ago
Description
In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.